Repigmentation of Hair Following Adalimumab Therapy
January 2015
in “
Dermatology online journal
”
Studysummary This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
A patient with rheumatoid arthritis (RA) experienced repigmentation of her hair from grey-white to dark brown-black following adalimumab therapy. Despite stable control of her RA and no recent changes in her medical regimen, the patient observed increased pigmentation in her hair, which continued even after switching to golimumab due to increased RA activity. This case was notable as it was the first reported instance of hair repigmentation associated with a tumor necrosis factor (TNF) inhibitor, highlighting a rare side effect of drug-induced changes in hair color.
